Nonprofit pharmaceutical company Civica has released it's biosimilar version of Lantus long-acting insulin for $55 for a box of 5 pens—that's the list price it costs you to buy it without needing insurance, coupons, or patient assistance programs. We look at how a nonprofit business model can drastically lower prices for patients and governments.

Things we talk about:

• More info about Civica insulin and CalRx Insulin

• CalRx Patient Advisory Council Charter

• Episode on insulin pricing

• Episode on co-pay cap laws

• 119th Congress pro-healthcare scorecard

Support Beta Cell on Patreon.

Diabetics are stuck in an abusive relationship with pharmaceutical corporations: if we try to fight to make insulin more affordable, they can simply stop distributing it, leaving us without the very thing we need to survive. We look back at the last decade of insulin access advocacy to see how advocates walk the line between progress and ruin.

Things we talk about:

• Beta Cell Action
• T1International

Support Beta Cell on Patreon.

Dexcom's new sensor replacement policy has shown what the company cares about most: your money.

Things we mention:

• Dexcom's sensor replacement policy
• Comparison of G7 and Libre 3 Accuracy
• Write to your representatives about Dexcom's policy (from Beta Cell Action)

Support Beta Cell on Patreon.